Molecular Imaging and Nanomedicine (LOMIN)

The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

The Laboratory of Molecular Imaging and Nanomedicine (LOMIN) specializes in synthesizing molecular imaging probes for positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical (bioluminescence, fluorescence and Raman), contrast enhanced ultrasound, photoacoustic imaging, as well as multimodality imaging. This research group aims to develop a molecular imaging toolbox for better understanding of biology, early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development. LOMIN puts special emphasis on high-sensitivity nanosensors for biomarker detection and theranostic nanomedicine for imaging, gene and drug delivery, and monitoring of treatment.

LOMIN group photo
Photo: C. Chang for NIBIB

Click here for LOMIN alumni contact information




The BMIS identifies disease-specific biomarkers, develops molecular imaging probes and tests probes for multimodality imaging, and characterizes imaging agents.
The CRS develops radionuclides and fluorophores for diagnostic imaging, conjugation methods for targeted delivery, and activatable probes to treat disease.
Theranostic Nanomedicine applies nanobiotechnology, a highly specific medical intervention at the nanoscale, for diagnosing, curing or preventing diseases.